CGRP DIAGNOSTICS

CGRP Diagnostics - A Novel Patented Companion Diagnostic for anti-CDRP Antibodies to give your drug a competitive advantage and increase market share... Anti-CGRP therapy is the biggest advance in migraine treatment in 30 years - but it only works for about 50% of patients, and is often reserved until after multiple treatment failures. To date, it has been impossible to identify which patients, pre-treatment, are likely to respond to anti-CGRP drugs of any kind. All that has now changed…... A Harvard Medical School discovery identified non-ictal allodynia as the key to accurately predicting pre-treatment anti-CGRP therapy response. Together with CGRP Diagnostics, they developed the world's first neurology "theranostic" - a proprietary Treatment Outcome Predictor test, clinically validated to prospectively identify which patients will, or won't, respond to anti-CGRP therapy - transforming migraine management for patients, clinicians and payors.